|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||1.40 - 1.64|
|52 Week Range||1.40 - 1.64|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
On a per-share basis, the Tel Aviv, Israel-based company said it had a loss of 9 cents. The company's shares closed at $1.35. A year ago, they were trading at $1.91. _____ This story was generated by Automated ...
SAN DIEGO, Oct. 31, 2017 /PRNewswire/ -- Arcturus Therapeutics, Inc., a leading RNA medicines company, and Synthetic Genomics, Inc. announced today that they have entered into a research collaboration and worldwide license agreement to develop self-amplifying RNA-based vaccines and therapeutics in both human and animal health. The collaboration will bring together Arcturus's LUNAR™ lipid-mediated delivery platform with Synthetic Genomics' RNA replicon platform to potentially enable more efficacious and lower cost vaccines and therapeutics.
NEW YORK, NY / ACCESSWIRE / October 20, 2017 / Alcobra headed higher on Thursday after the company's wholly-owned subsidiary Arcturus entered into a research collaboration and worldwide license agreement ...
If you are looking to invest in Alcobra Ltd’s (NASDAQ:ADHD), or currently own the stock, then you need to understand its beta in order to understand how it can affectRead More...
On a per-share basis, the Tel Aviv, Israel-based company said it had a loss of 13 cents. The company's shares closed at $1.03. A year ago, they were trading at $4.91. _____ This story was generated by ...
Research Desk Line-up: Alcobra Post Earnings Coverage LONDON, UK / ACCESSWIRE / June 26, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Gilead Sciences, ...
Shire has won U.S. approval for a long-acting attention deficit drug aimed at adolescents and adults, boosting its stock of medicines for the cognitive condition that affects millions of children and is being diagnosed more in older people. The U.S. Food and Drug Administration (FDA) green light for Mydayis follows good results for Shire's new hereditary angioedema drug and helps offset the setback of early generic competition to a Shire drug for ulcerative colitis. Shares in Dublin-based Shire rose 1.5 percent by 0800 GMT in London on Wednesday following the overnight FDA news.
Swiss biotech NLS Pharma AG said on Wednesday mid-stage trial data showed that its drug to treat attention deficit hyperactivity disorder (ADHD) greatly reduced symptoms in adults, paving the way for a late-stage trial. ADHD is a chronic condition characterized by hyperactivity, impulsive behavior and a difficulty in sustaining focus. NLS' drug, mazindol, is a non-stimulant, but trial data showed it could be as effective as a stimulant.
The Tel Aviv, Israel-based company said it had a loss of 13 cents per share. The company's shares closed at $1.13. A year ago, they were trading at $5.12. _____ This story was generated by Automated Insights ...